argenex SE (NASDAQ:ARGX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of argenex SE (NASDAQ:ARGX) have earned an average rating of “Moderate Buy” from the twenty-four research firms that are covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $1,034.5556.

ARGX has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $940.00 target price on shares of argenex in a report on Thursday, June 25th. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a report on Monday, April 20th. Wedbush restated an “outperform” rating and issued a $1,000.00 price target on shares of argenex in a research report on Thursday, June 11th. Guggenheim upped their price objective on shares of argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Finally, Bank of America raised their price objective on shares of argenex from $1,016.00 to $1,088.00 and gave the stock a “buy” rating in a report on Thursday.

Institutional Investors Weigh In On argenex

Large investors have recently bought and sold shares of the business. M&T Bank Corp grew its holdings in argenex by 20,977.7% during the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after acquiring an additional 774,916 shares during the last quarter. Sands Capital Management LLC increased its position in argenex by 2,046.6% in the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock valued at $300,110,000 after acquiring an additional 340,245 shares in the last quarter. Invesco Ltd. raised its stake in shares of argenex by 390.4% in the fourth quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock worth $350,178,000 after acquiring an additional 331,489 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of argenex by 80.1% in the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after acquiring an additional 324,653 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in shares of argenex by 570.3% during the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after purchasing an additional 250,278 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenex Price Performance

Shares of ARGX stock opened at $939.68 on Friday. The stock’s fifty day simple moving average is $838.05 and its 200 day simple moving average is $810.26. argenex has a one year low of $536.02 and a one year high of $953.58. The firm has a market cap of $58.44 billion, a price-to-earnings ratio of 41.84, a P/E/G ratio of 1.39 and a beta of 0.45.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. The firm had revenue of $1.31 billion during the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%. On average, research analysts anticipate that argenex will post 26.19 earnings per share for the current year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.